MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
53.8 M |
Market Cap[1] |
$ 509 M |
EBITDA (LTM) |
$ -256 M |
P/E (LTM) |
-1.82 |
P/S (LTM) |
48.3 |
EPS (LTM) |
-5.24 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aclaris Therapeutics
ACRS
|
$ 2.87 | -4.82 % | $ 222 M | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.17 | 3.0 % | $ 7.63 B | Nasdaq Capital Market |  Australia |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | -2.51 % | $ 495 M | Nasdaq Global Select Market | Britain |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 213.02 | -0.1 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.19 | -0.8 % | $ 724 M | NYSE | USA |
 |
BioVie
BIVI
|
$ 1.18 | 1.72 % | $ 1.74 M | Nasdaq Capital Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 96.58 | 1.45 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.2 | -2.45 % | $ 435 M | NYSE American |  Israel |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 26.36 | -1.57 % | $ 1.28 B | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Catalyst Biosciences
CBIO
|
$ 11.63 | -1.94 % | $ 766 M | Nasdaq Capital Market | USA |
 |
Anika Therapeutics
ANIK
|
$ 9.59 | -0.26 % | $ 141 M | Nasdaq Global Select Market,SPB | USA |
 |
Certara
CERT
|
$ 8.75 | -0.68 % | $ 1.4 B | Nasdaq Global Select Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 560.61 | -1.29 % | $ 42.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Celldex Therapeutics
CLDX
|
$ 27.1 | -0.22 % | $ 1.75 M | Nasdaq Global Select Market | USA |
 |
Cellectis S.A.
CLLS
|
$ 4.83 | -0.21 % | $ 116 M | Nasdaq Global Market | France |
 |
Cellectar Biosciences
CLRB
|
$ 3.33 | 12.71 % | $ 40.7 M | Nasdaq Capital Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.75 | 5.77 % | $ 17.3 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 92.01 | 0.09 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.